KLK3 and prostate cancer: Thus a “PSA screening era” beginning in 1988, FDA approved in 1992, and peaking between 1992 and 1998 has been referred to as a period in which prostate cancers diagnosed by serum PSA alone encompassed a variety of stages of prostate cancers, including clinically indolent cancers [4, 7].